BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 25440022)

  • 1. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
    Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
    Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and genetic profile of patients with medullary thyroid cancer treated in the Cancer Centre--Institute of Oncology in Warsaw].
    Czetwertyńska M; Kozłowicz-Gudzińska I; Stachlewska-Nasfeter E; Sromek M; Skasko E; Paszko Z
    Endokrynol Pol; 2006; 57(4):415-9. PubMed ID: 17006846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades.
    Sarika HL; Papathoma A; Garofalaki M; Saltiki K; Pappa T; Pazaitou-Panayiotou K; Anastasiou E; Alevizaki M
    Eur J Endocrinol; 2015 Apr; 172(4):501-9. PubMed ID: 25624014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
    Frank-Raue K; Rondot S; Schulze E; Raue F
    Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M; Weinhüsel A; Niederle B; Haas OA
    Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
    Fitze G; Saeger HD; Roesner D; Schackert HK
    Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
    Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds.
    Martins-Costa MC; Cunha LL; Lindsey SC; Camacho CP; Dotto RP; Furuzawa GK; Sousa MS; Kasamatsu TS; Kunii IS; Martins MM; Machado AL; Martins JR; Dias-da-Silva MR; Maciel RM
    Endocr Relat Cancer; 2016 Dec; 23(12):909-920. PubMed ID: 27807060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
    Menon MM; Simha MR
    Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
    Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
    Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
    Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan.
    Chang CF; Yang WS; Su YN; Wu IL; Chang TC
    J Formos Med Assoc; 2009 May; 108(5):402-8. PubMed ID: 19443294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple endocrine neoplasia type 2: 2007 update.
    Raue F; Frank-Raue K
    Horm Res; 2007; 68 Suppl 5():101-4. PubMed ID: 18174721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.
    Romei C; Mariotti S; Fugazzola L; Taccaliti A; Pacini F; Opocher G; Mian C; Castellano M; degli Uberti E; Ceccherini I; Cremonini N; Seregni E; Orlandi F; Ferolla P; Puxeddu E; Giorgino F; Colao A; Loli P; Bondi F; Cosci B; Bottici V; Cappai A; Pinna G; Persani L; Verga U; Boscaro M; Castagna MG; Cappelli C; Zatelli MC; Faggiano A; Francia G; Brandi ML; Falchetti A; Pinchera A; Elisei R;
    Eur J Endocrinol; 2010 Aug; 163(2):301-8. PubMed ID: 20516206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.
    Frank-Raue K; Rondot S; Raue F
    Mol Cell Endocrinol; 2010 Jun; 322(1-2):2-7. PubMed ID: 20083156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.